Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Genitourinary (GU) Tumors”

12 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 12 of 12 results

Testing effectiveness (Phase 2)Ended earlyNCT02612194
What this trial is testing

LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer

Who this might be right for
Urinary Bladder NeoplasmsUreteral NeoplasmsUrethral Neoplasms
Wake Forest University Health Sciences 8
Not applicableUnknownNCT04870567
What this trial is testing

HDR Brachytherapy vs SABR in Early-intermediate Prostate Cancer

Who this might be right for
Biochemical Relapse Free SurvivalComplications Rates (Erectile Dysfunction, GI, GU Complications)
N.N. Petrov National Medical Research Center of Oncology 350
Not applicableStudy completedNCT01056562
What this trial is testing

An Alternative to A Fixed Schedule In Management Of Prostate Cancer

Who this might be right for
Prostate Cancer
University Health Network, Toronto 82
Not applicableLooking for participantsNCT06795087
What this trial is testing

Discharge Medication Use Post-Operatively in GU Cancer Patients

Who this might be right for
Genitourinary Cancer
Wake Forest University Health Sciences 684
Not applicableEnded earlyNCT02164942
What this trial is testing

LCI-GU-BLA-SPEC-001: Aurora Kinase Expression in Muscle-Invasive Bladder Cancer

Who this might be right for
Bladder Cancer
Wake Forest University Health Sciences 6
Not applicableEnded earlyNCT03134027
What this trial is testing

Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) Model of Genitourinary (GU) Cancers

Who this might be right for
Genito Urinary CancerBladder CancerKidney Cancer+1 more
Duke University 3
Not applicableNot Yet RecruitingNCT07483658
What this trial is testing

Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.

Who this might be right for
Reccurent/Metastatic Solid Tumor DiseaseProstate Cancer (Post Prostatectomy)Prostate Cancer+3 more
CHU de Quebec-Universite Laval 434
Testing effectiveness (Phase 2)Ended earlyNCT01685255
What this trial is testing

The IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy

Who this might be right for
Ovarian CancerGenitourinary (GU) Tumors
Incyte Corporation 83
Large-scale testing (Phase 3)Ended earlyNCT01410565
What this trial is testing

Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer

Who this might be right for
Bladder Cancer
Spectrum Pharmaceuticals, Inc 66
Large-scale testing (Phase 3)Ended earlyNCT05171075
What this trial is testing

A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

Who this might be right for
Venous ThromboembolismDeep Venous ThrombosisPulmonary Embolism
Anthos Therapeutics, Inc. 417
Large-scale testing (Phase 3)Ended earlyNCT01469221
What this trial is testing

Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)

Who this might be right for
Bladder Cancer
Spectrum Pharmaceuticals, Inc 47
Not applicableActive Not RecruitingNCT04761107
What this trial is testing

Impact of COVID-19 on GU Disease

Who this might be right for
COVID-19 InfectionGenitourinary CancerBenign Urologic Conditions
Icahn School of Medicine at Mount Sinai 15,240